A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
Synapse pathology in psychiatric and neurologic disease
J., & Mohiuddin, S
Researchers investigate GHK-Cu in studies involving: .Cellular communication .Extracellular matrix biology .Collagen-related protein expression .Elastin biology .Oxidative stress mechanisms .Fibroblast signaling .Copper-dependent biological pathways .Tissue remodeling research .Biomaterial compatibility .Cosmetic science research Because these biological systems interact closely, GHK-Cu has become a valuable peptide for multidisciplinary research projects involving biotechnology, peptide chemistry, molecular biology, and cosmetic formulation science
Emerging research suggests that copper peptides such as GHK-Cu may support collagen signaling, wound repair pathways, and anti-inflammatory activity, aligning with evidence informed anti-aging strategies
